OverviewSuggest Edit

NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory diseases. The Company's NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact; antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high-affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and Target-activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

TypePublic
Founded2014
HQCulver City, US
Websitenantkwest.com
Employee Ratings2.3

Latest Updates

Employees (est.) (Dec 2018)161(+16%)
Job Openings25
Revenue (FY, 2019)$43 K(-8%)
Share Price (Sept 2020)$8.3 (+2%)
Cybersecurity ratingAMore

Key People/Management at NantKwest

Patrick Soon-Shiong

Patrick Soon-Shiong

Chairman, Chief Executive Officer
Barry J. Simon

Barry J. Simon

President, Chief Administrative Officer, Director
John C. Thomas

John C. Thomas

Director & Chairman, Audit Committee
Hans G. Klingemann

Hans G. Klingemann

Vice President, Research & Development
Fred Driscoll

Fred Driscoll

Lead Independent Director
Leonard S. Sender

Leonard S. Sender

SVP, Medical Affairs for Pediatric, Adolescent and Young Adult Oncology
Show more

NantKwest Office Locations

NantKwest has offices in Culver City, San Diego and Woburn
Culver City, US (HQ)
9920 Jefferson Blvd
San Diego, US
3530 John Hopkins Ct
Woburn, US
19 Presidential Way #104
Show all (3)

NantKwest Financials and Metrics

NantKwest Revenue

NantKwest's revenue was reported to be $43 k in FY, 2019
USD

Revenue (Q2, 2020)

1.0k

Net income (Q2, 2020)

(20.1m)

EBIT (Q2, 2020)

(20.2m)

Market capitalization (17-Sept-2020)

899.4m

Closing stock price (17-Sept-2020)

8.3

Cash (30-Jun-2020)

102.7m

EV

806.2m
NantKwest's current market capitalization is $899.4 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

44.0k45.0k47.0k43.0k

Revenue growth, %

2%4%

General and administrative expense

95.4m57.1m42.7m18.1m

R&D expense

29.2m42.0m55.7m49.8m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

6.0k12.0k12.0k11.0k14.0k8.0k5.0k4.0k31.0k5.0k17.0k12.0k21.0k1.0k

General and administrative expense

26.7m28.6m24.4m16.2m14.1m13.4m14.3m13.6m9.6m5.7m4.2m4.0m5.4m6.5m

R&D expense

4.9m6.4m8.4m9.2m9.7m11.1m14.0m14.7m14.6m12.6m13.1m12.1m13.2m13.7m

Operating expense total

31.6m35.0m32.8m25.5m23.8m24.5m28.3m28.3m24.1m18.3m17.3m16.1m18.6m20.2m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

175.9m8.1m23.9m16.8m15.5m

Accounts Receivable

363.0m

Prepaid Expenses

4.2m13.8m4.1m

Current Assets

205.1m132.5m88.8m55.8m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

120.4m358.6m63.3m38.2m31.4m13.6m39.0m20.9m11.2m16.1m15.3m22.3m17.3m18.3m17.0m102.7m

Accounts Receivable

45.0k

Prepaid Expenses

388.0k1.7m3.8m5.2m4.9m6.0m4.5m5.0m4.7m16.4m13.6m2.7m5.6m3.9m4.7m

Current Assets

120.9m360.3m225.5m218.0m214.5m195.9m181.6m156.9m126.8m110.1m100.6m113.4m87.0m71.6m44.1m115.3m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(236.9m)(120.8m)(96.4m)(96.2m)(65.8m)

Depreciation and Amortization

1.5m4.6m5.6m9.6m9.0m

Accounts Payable

627.0k888.0k150.0k(1.1m)(12.0m)

Cash From Operating Activities

(25.3m)(38.6m)(48.8m)(63.4m)(61.4m)
USDQ2, 2015

Financial Leverage

1 x
Show all financial metrics

NantKwest Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

NantKwest Online and Social Media Presence

Embed Graph

NantKwest News and Updates

Thinking about buying stock in Virgin Galactic, Miragen Therapeutics, Nantkwest Inc, Agenus Inc, or Norwegian Cruise Line?

NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPCE, MGEN, NK, AGEN, and NCLH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Natural Killer Cells Market Prognosticated For A Ravishing Growth By 2026 Global Key Players NantKwest, NKT Therapeutics Inc, AvidBiotics, Glycostem, Sorrento Therapeutics, Inc., CellGenix GmbH, Lonza and R&D Systems, Inc.

#Summary: Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twitter…

NantKwest Blogs

Engineered killer immune cells target tumours and their immunosuppressive allies

The post Engineered killer immune cells target tumours and their immunosuppressive allies appeared first on NantKwest.

NantKwest Announces Closing of $90.7 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 29, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock

NantKwest Announces Pricing of Public Offering of Common Stock

NantKwest Announces Pricing of Public Offering of Common Stock Content Import Thu, 06/25/2020 - 01:01 NantKwest Announces Pricing of Public Offering of Common Stock Jun 25, 2020 | Press Releases This release is a backfill from a News Wire Genera…

NantKwest Announces Proposed Public Offering of Common Stock

EL SEGUNDO, Calif. --(BUSINESS WIRE)--Jun. 24, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public

NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested

NantKwest’s antibody-targeted NK cell line, haNK, which is engineered for increased antibody-dependent cell-mediated cytotoxicity and activation, showed increased resistance to hypoxic conditions as seen in suppressive tumor microenvironments NantKwest’s PD-L1 t-haNK cells, haNK cells engineered

NantKwest Announces Studies in collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested

The post NantKwest Announces Studies in collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested appeared first on NantKwest.
Show more

NantKwest Frequently Asked Questions

  • When was NantKwest founded?

    NantKwest was founded in 2014.

  • Who are NantKwest key executives?

    NantKwest's key executives are Patrick Soon-Shiong, Barry J. Simon and John C. Thomas.

  • How many employees does NantKwest have?

    NantKwest has 161 employees.

  • What is NantKwest revenue?

    Latest NantKwest annual revenue is $43 k.

  • What is NantKwest revenue per employee?

    Latest NantKwest revenue per employee is $267 .

  • Who are NantKwest competitors?

    Competitors of NantKwest include Cullinan Oncology, Cugene and Forbius.

  • Where is NantKwest headquarters?

    NantKwest headquarters is located at 9920 Jefferson Blvd, Culver City.

  • Where are NantKwest offices?

    NantKwest has offices in Culver City, San Diego and Woburn.

  • How many offices does NantKwest have?

    NantKwest has 3 offices.